
|Articles|February 26, 2007
Helixate FS, Mix2Vial now packaged together
Advertisement
CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
2
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
3
HHS Claims ACIP Cannot Meet for Flu Season Due to Ongoing Legal Battle
4
US Controlled Substance Market Expected to Grow $21 Billion by 2035
5




































